NCT03234907 - Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

August 14, 2020

Study Completion Date

August 14, 2020

Conditions

Crohn's Disease

Interventions

DRUG

Vedolizumab IV

Vedolizumab IV infusion

DRUG

Placebo

Vedolizumab placebo-matching

Trial Locations (29)

100050

Gastroenterology, Beijing

100730

Gastroenterology, Beijing

110022

Gastroenterology, Shenyang

130000

Gastroenterology, Changchun

200025

Gastroenterology, Shanghai

200032

Gastroenterology, Shanghai

200072

Gastroenterology, Shanghai

200092

Gastroenterology, Shanghai

210008

Gastroenterology, Nanjing

210029

Gastroenterology, Nanjing

230024

Gastroenterology, Hefei

241023

Gastroenterology, Wuxi

310009

Gastroenterology, Hangzhou

310016

Gastroenterology, Hangzhou

330006

Gastroenterology, Nanchang

350025

Gastroenterology, Fuzhou

361004

Gastroenterology, Xiamen

400037

Gastroenterology, Chongqing

410008

Gastroenterology, Changsha

410011

Gastroenterology, Changsha

410013

Gastroenterology, Changsha

430000

Gastroenterology, Wuhan

430030

Gastroenterology, Wuhan

430060

Gastroenterology, Wuhan

510080

Gastroenterology, Guangzhou

510515

Gastroenterology, Guangzhou

510655

Gastroenterology, Guangzhou

610041

Gastroenterology, Chengdu

650032

Gastroenterology, Kunming